At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 76 enrolled
Drug / intervention
TLC599 LD group +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IIa, Randomized, Double Blinded, Placebo Controlled, Dose Finding Study for Single Dose Administration of TLC599 in Patients With Osteoarthritis (OA) of Knee
In Brief
A Phase 2 clinical trial evaluating TLC599 LD group, Normal Saline, and 1 other intervention for Osteoarthritis of the Knee. Completed, enrolled 76 participants across 13 sites in 2 countries.
Detailed Summary
This trial is a Phase IIa, Randomized, Double blinded, Placebo controlled, Dose finding Study to investigate the safety and efficacy of TLC599 in subjects with osteoarthritis of the knee.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis of the Knee
CountriesAustralia, Taiwan
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedDec 2016
Enrollment StartMar 2017
Primary CompletionJul 2018
TodayJul 2026
First PostedDec 29, 2016
Enrollment StartMar 16, 2017
Primary CompletionJul 4, 2018
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 9.5 years ago
Interventions
TLC599 LD groupdrug
Single dose via intra-articular injection
Normal Salinedrug
Single dose via intra-articular injection
TLC599 HD groupdrug
Single dose via intra-articular injection